Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SZ011 in advanced triple negative breast cancer
NCT05686720Phase 1Unknown
- Sponsor
- The First Affiliated Hospital of Shantou University Medical College
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SZ011 CAR-NK in triple-negative breast cancer (TNBC), sponsored by The First Affiliated Hospital of Shantou University Medical College. Primary endpoints: Number of Adverse Events at 6 months and Objective Response Rate at 6 months. Status: unknown.
02
Drugs
SZ011 CAR-NK
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05686720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686720.